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May 2015 Letters to the Editor 265overexpression cannot be taken as equal with execution of
necroptosis. However, we can now demonstrate that the
phosphorylated form of the protein mixed-lineage-like ki-
nase (p-MLKL), which is considered to be the executional
kinase of necroptosis,12 can be detected in human NASH
livers (Figure 1) and that it strikingly resembles the gran-
ular staining patterns of RIP3 in NASH patients.3
Independently of experimental questions in mouse
models, we believe that the activation of a known cell-death
pathway in hepatocytes in human NASH patients justiﬁes
further exploration as a pharmacologic target, potentially as
a complementary target to mediators of apoptosis.
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University Hospital RWTH Aachen
Aachen, GermanyFigure 1. NASH-induced liver injury is decreased in
hepatocyte-speciﬁc caspase 8 knockout mice (caspase
8Dhepa). Wild-type mice and mice carrying a hepatocyte-
speciﬁc deletion of caspase 8 were fed the FFC diet (a
NASH-inducing diet high in saturated fats, fructose, and
cholesterol) for 3 months, and serum alanine transaminase
activity was measured. P value was calculated using unpaired
two-tailed t test.References
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http://dx.doi.org/10.1016/j.jcmgh.2015.02.001Reply: We appreciate the interest and thoughtful
comments of Dr Luedde and colleagues on our
review, “Death Receptor-Mediated Cell Death andProinﬂammatory Signaling in Nonalcoholic Steatohepati-
tis.”1 As they have made several seminal insights regarding
liver pathobiology, we are ﬂattered that our perspectives on
nonalcoholic steatohepatitis (NASH), particularly on nec-
roptosis in NASH, triggered their interest. We are happy to
continue a friendly scientiﬁc dialogue.
They noted, the ideal model of NASH is a matter of
intense discussion. We highlight that animals on
methionine-choline-deﬁcient (MCD) diet lose weight andlack insulin resistance, which is in direct contrast to humans
with NASH. From our perspective, the MCD diet model is not
informative regarding the mechanisms of steatohepatitis
occurring in the context of the metabolic syndrome, and the
use of this model should be discouraged.
It is well established that cell death by necroptosis re-
quires that caspase 8 activity be inhibited or disrupted. This
requirement may challenge the biological relevance of nec-
roptosis in human liver disease. Currently, only a few con-
ditions are known that lead to disrupted caspase 8 function
in humans.2 For instance, a caspase 8 deﬁciency state
(CEDS), caused by a loss-of-function mutation in the
caspase 8 gene, is a very rare genetic disorder of the im-
mune system with no liver phenotype.3,4 Several viruses and
intracellular bacteria may express proteins interfering with
caspase 8 activation and can sensitize cells to necroptosis.5
However, this is not a feature of common hepatotropic vi-
ruses such as hepatitis C or B viruses. To date, loss of cas-
pase 8 in steatohepatitis has not been reported. Finally, in
preclinical studies of NASH, pharmacologic inhibition of
caspases have been associated with beneﬁcial effects,
including reduced hepatocyte cell death.6–8
As Dr Luedde and colleagues point out, caspase 8 dele-
tion in intestinal or skin epithelium causes receptor-
interacting serine/threonine-protein kinase 3 (RIP3)-
dependent injury in mice. Similarly, necroptosis may occur
266 Letters to the Editor Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 3in caspase 8/ mice fed a MCD-diet,9 but these ﬁndings
cannot be simply extrapolated to a situation where caspase
8 is fully functional, such as during NASH. Studies using
caspase 8/ mice are thus contrived because of the forced
caspase 8 deletion. In addition, for interpretation of pre-
clinical studies using caspase 8/ mice, one should bear in
mind that mice possess caspase 8, but humans express
caspase 8 and caspase 10, with overlapping functions.
Finally, the presence of increased protein levels with RIP3
does not provide proof that necroptosis occurred.10 It
should also be noted that RIP3 can form complexes such as
the ripoptosome, which induce apoptosis.10
We had the opportunity to experimentally interrogate
mice carrying a hepatocyte-speciﬁc deletion of caspase 8
(caspase 8Dhepa), which had been generated by Dr Luedde’s
colleagues.11 When these mice were fed an established
NASH-inducing diet high in saturated fats, fructose, and
cholesterol (FFC diet),12 they displayed reduced liver injury
compared with wild-type mice as assessed by serum alanine
transaminase (ALT) values (Figure 1) and histology (data
not shown). Of note, the serum ALT values of these mice
were in the range of the ALT values normally seen in
healthy mice. The differences between our experience and
that of the authors may relate to the NASH model employed.
Of note, the FFC diet is the only model that has been
demonstrated to recapitulate the chicken-wire pattern of
pericellular ﬁbrosis of human NASH occurring in the context
of obesity, nutrient excess, and insulin resistance.12
In conclusion, the precise role of necroptosis in human
disease remains debatable, and there is not yet convincing
evidence that caspase 8 deﬁciency occurs in any acquiredhuman liver disease. Therefore, we view the likelihood that
necroptosis occurs in NASH as unlikely.
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GREGORY J. GORES, MD




1. Hirsova P, et al. Cell Mol Gastroenterol Hepatol 2015;
1:17–27.
2. Ashkenazi A, et al. Annu Rev Cell Dev Biol 2014;
30:337–356.
3. Chun HJ, et al. Nature 2002;419:395–399.
4. Su HC, et al. Immunol Allergy Clin North Am 2008;
28:329–351.
5. Linkermann A, et al. N Engl J Med 2014;370:4554–4565.
6. Barreyro FJ, et al. Liver Int 2015;35:953–966.
7. Anstee QM, et al. J Hepatol 2010;53:542–550.
8. Witek RP, et al. Hepatology 2009;50:1421–1430.
9. Gautheron J, et al. EMBO Mol Med 2014;6:1062–1074.
10. Pasparakis M, et al. Nature 2015;517:311–320.
11. Liedtke C, et al. Gastroenterology 2011;141:2176–2187.
12. Charlton M, et al. Am J Physiol Gastrointest Liver Physiol
2011;301:G825–G834.
Conﬂicts of interest
The authors disclose no conﬂicts.
http://dx.doi.org/10.1016/j.jcmgh.2015.03.001
